

April 7, 2010

## Archimica reports strong growth in 2009

**Schiphol/The Netherlands, 7th April 2010 – Archimica announces sales of €131 million for the year to 31st December 2009, a 16% growth versus 2008. Gross profit, operating profit and free cash flow all increased substantially in 2009 driven by the sales growth.**

At 31st December 2009, Archimica had a positive net cash balance with ample liquidity to implement the previously announced significant 2010 investment programme. James Harrison, CEO, stated: "I would like to thank our customers and suppliers for their continued support, and our employees for achieving an exceptionally strong 2009 performance during difficult times for our industry and the world economy.

The pharmaceutical industry is changing rapidly – from our manufacturer perspective, our innovator and generic customers are blurring together. We believe that the best-in-class manufacturing partner of the future must be a trustworthy expert and have a strong track-record in on-patent and off-patent pharmaceutical product delivery. Archimica recognised these industry dynamics early, and is delivering on our milestone plan to achieve these strategic goals.

We aim to build on our solid 2009 performance in 2010 and well into the future by leveraging our leading product pipeline. We believe that an important aspect of best-in-class performance is providing products that can lower overall drug manufacturing costs. T3P<sup>®</sup> is our flagship product in this area. It is a coupling agent for the final steps of API synthesis that can provide yield improvements and throughput benefits to 100+ APIs. Pharmaceutical cost pressures are higher than ever. We look forward to working with customers to help reduce both on-patent and off-patent drug delivery costs."

Further information on Archimica products can be found at [www.archimica.com](http://www.archimica.com).

---

### Archimica – Strong. Steady. Focused on Pharmaceuticals.

Archimica is a privately held leading pharmaceutical fine chemicals company that combines world-scale chemical manufacturing experience with a history of pharmaceutical commercialisation that stretches back over 40 years. Archimica is particularly focused on the custom synthesis of innovative building blocks, intermediates and APIs in close cooperation with its clients. The company has approximately 600 employees at six production sites in Italy, France, Germany, US and UK and sales of € 131 million in 2009. Archimica's core technologies are its T3P<sup>®</sup> technology for high-performance amide-/peptide bond formations and other cost-reducing condensations, cryogenic reactions especially for boronic acids, Lithium chemistry, Pd-catalyzed chemistries for biaryls and C,X-couplings, hydrogenations up to 80 bar, heterocyclic products, enzymatic chemistries, nitrations and aseptic filtration for bulk steriles. Production facilities at all scales up to very large volumes (> 20 m<sup>3</sup> reactors) are available for substantial economies of scale for large-volume products.